Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Size By Type (Trabecular, Suprachoroidal), By Application (Hospital, Ambulatory surgical centers), By Region, And Segment Forecasts, 20...

The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market was valued at USD 1.6 billion in 2023 and is projected to reach USD 4.1 billion by 2031, expanding at a CAGR of 12.6% during the forecast period (2023–2031). The rising global prevalence of glaucoma, coupled with the growing preference for safer, less invasive treatment options, is propelling the demand for MIGS devices. These devices offer a lower risk profile and faster recovery time compared to traditional glaucoma surgeries, making them increasingly attractive to both ophthalmologists and patients. Technological advancements and a strong pipeline of new product launches further accelerate market expansion.

Drivers:

1. Increasing Glaucoma Incidence:

An aging population and growing awareness of early glaucoma detection are key drivers behind the increasing demand for MIGS devices. Glaucoma remains one of the leading causes of irreversible blindness globally, spurring interest in preventive and minimally invasive treatment options.

2. Technological Innovations in Ophthalmic Devices:

Advancements in micro-stent designs, drug delivery systems, and imaging technologies have significantly improved the safety and efficacy of MIGS procedures. Companies are continuously innovating to develop devices that are easy to implant and deliver superior outcomes.

3. Preference for Minimally Invasive Procedures:

Surgeons and patients alike are increasingly favoring minimally invasive solutions due to their reduced risk of complications, minimal postoperative care requirements, and quicker recovery compared to traditional trabeculectomy and tube shunt surgeries.

Restraints:

1. High Cost of MIGS Devices:

The premium pricing of MIGS devices and associated surgical tools may limit their adoption, particularly in developing countries or regions with constrained healthcare budgets.

2. Limited Insurance Reimbursement:

In many markets, reimbursement for MIGS procedures is limited or inconsistent, creating a barrier for both patients and healthcare providers.

Opportunity:

1. Expanding Access in Emerging Markets:

Rising investments in healthcare infrastructure, increasing patient awareness, and supportive regulatory policies in emerging economies like India, Brazil, and China present untapped growth opportunities for MIGS device manufacturers.

2. Growing Adoption of Combination Surgeries:

The increasing adoption of MIGS procedures in conjunction with cataract surgery is creating a dual treatment pathway, encouraging broader utilization of these devices.

Market by System Type Insights:

Among the system types, stent-based MIGS devices held the largest market share in 2023. These devices, such as iStent and Hydrus Microstent, are widely used due to their established safety profiles and long-term efficacy. The implant-free MIGS segment, including devices like the Trabectome and Kahook Dual Blade, is expected to register the fastest growth, driven by ongoing clinical adoption and favorable patient outcomes.

Market by End-use Insights:

In terms of end-use, ambulatory surgical centers (ASCs) emerged as the leading segment, contributing to over 45% of the market share in 2023. The trend toward outpatient ophthalmic procedures, combined with cost efficiency and reduced hospital stays, supports this dominance. Meanwhile, hospital-based ophthalmic departments are projected to witness robust growth due to an increasing volume of complex glaucoma cases being managed in tertiary care settings.

Market by Regional Insights:

North America led the global MIGS devices market in 2023, owing to high disease prevalence, widespread awareness, favorable reimbursement policies, and strong R&D activities. However, Asia-Pacific is poised to grow at the fastest CAGR over the forecast period, driven by a rapidly aging population, growing middle-class healthcare spending, and increased access to ophthalmic care in countries like China and India.

Competitive Scenario:

Leading players in the Global MIGS Devices Market include Glaukos Corporation, Alcon Inc., Ivantis Inc. (now part of Alcon), Sight Sciences Inc., Santen Pharmaceutical Co., Ltd., New World Medical Inc., and MicroSurgical Technology (MST). These companies are focusing on strategic mergers and acquisitions, regulatory approvals, and new product launches to expand their market presence.

Key Developments:

In 2023, Alcon completed the acquisition of Ivantis, enhancing its glaucoma portfolio with the Hydrus Microstent.

Glaukos received expanded FDA approval for its iStent Infinite in 2022, enabling broader clinical use.

Sight Sciences launched new clinical studies in 2024 to support broader adoption of OMNI Surgical System in combination procedures.

Scope of Work – Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market

Report Metric Details

Market Size (2023) USD 1.6 billion

Projected Market Size (2031) USD 4.1 billion

CAGR (2023–2031) 12.6%

Market Segments By System Type (Stent-Based, Shunt-Based, Implant-Free), End-use, Region

Growth Drivers Rising glaucoma prevalence, minimally invasive trend, technological advances

Opportunities Emerging markets, combined cataract-glaucoma surgeries

Key Market Developments:

2023: Alcon’s acquisition of Ivantis strengthened its glaucoma device portfolio with the FDA-approved Hydrus Microstent.

2022: Glaukos expanded indications for its iStent Infinite, allowing treatment in a broader glaucoma population.

2024: Sight Sciences initiated multi-center studies to evaluate the OMNI system's performance in mild-to-moderate glaucoma.

FAQs:

1) What is the current market size of the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?

The market was valued at USD 1.6 billion in 2023.

2) What is the major growth driver of the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?

The primary growth driver is the increasing preference for minimally invasive treatment options for glaucoma.

3) Which is the largest region during the forecast period in the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?

North America is expected to retain its position as the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?

The stent-based MIGS devices segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?

Key players include Glaukos Corporation, Alcon Inc., Sight Sciences Inc., and Santen Pharmaceutical Co., Ltd.

Would you like a downloadable version of this report description?